Table 3.
Patient characteristics of those with Biloma
| Mean DEB dose (mg) | Mean tumor burden (%) | |
|---|---|---|
| All (n = 13) | 80 | 29 |
| No biloma (n = 6) | 79 | 44 |
| Biloma (n = 7) | 85 | 12 |
| Patient no. | Disease presentationa | Biliary anastomosis | Ductal dilitation before DEB-TACE | Tumor burden | Time point biloma developed | Biloma volume (cm3) | Drainage/reason | Outcome from biloma/abscess |
|---|---|---|---|---|---|---|---|---|
| 1 | 2 | No | No | 9 | DEB-TACE no. 1 | 1.7 | No | No sequelae |
| 2 | 1 | No | No | 30 | DEB-TACE no. 2 | 2.3 | No | No sequelae |
| 3 | 2 | No | Yes | 20 | DEB-TACE no. 1 | 394.42 | Yes, mass effect | Resolved |
| 4 | 1 | No | No | 17 | DEB-TACE no. 1 | 68.6 | Yes, symptomatic for infection | Resolved |
| 5 | 0 | No | No | 10 | DEB-TACE no. 1 | 7.3 | No | Unknown: hospice; extrahepatic disease progression |
| 6 | 2 | Yes | No | 10 | DEB-TACE no. 1 | 55.3 | Yes, symptomatic for infection | Prolonged hospital course and infection; subsequent death |
| 7 | 0 | No | Yes | 4 | DEB-TACE no. 1 | 83.2 | Yes, symptomatic for infection | Prolonged hospital course and infection; subsequent death |
a
0 single lesion with or without satellites, 1 multiple lesions (smallest 3.5 cm), 2 diffuse, multiple lesions (largest 3.4 cm)